{"id":3854,"date":"2021-07-30T11:20:09","date_gmt":"2021-07-30T11:20:09","guid":{"rendered":"http:\/\/www.enyopharma.com\/fr\/?p=3854"},"modified":"2021-07-30T11:20:09","modified_gmt":"2021-07-30T11:20:09","slug":"enyo-pharma-annonce-les-premiers-resultats-intermediaires-du-vonafexor-eyp001-a-16-semaines-dans-deux-etudes-de-phase-2a-en-cours-chez-des-patients-atteints-dhepatite-b-chronique","status":"publish","type":"post","link":"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-les-premiers-resultats-intermediaires-du-vonafexor-eyp001-a-16-semaines-dans-deux-etudes-de-phase-2a-en-cours-chez-des-patients-atteints-dhepatite-b-chronique\/","title":{"rendered":"ENYO Pharma annonce les premiers r\u00e9sultats interm\u00e9diaires du Vonafexor (EYP001) \u00e0 16 semaines dans deux \u00e9tudes de phase 2a en cours chez des patients atteints d&#8217;h\u00e9patite B chronique"},"content":{"rendered":"<p>Lyon, France. Le 30 Juillet, 2021 &#8211; ENYO Pharma (ENYO), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui des donn\u00e9es de preuve de concept positives issues de l&#8217;\u00e9tude EYP001-203 de Vonafexor en association avec le pegInterf\u00e9ron chez des patients vir\u00e9miques atteints d&#8217;h\u00e9patite B chronique (CHB).<\/p>\n <a href=\"http:\/\/www.enyopharma.com\/wp-content\/uploads\/2021\/07\/20210730-CP-ENYO-on-201-et-203-studies-in-HBV-FINAL-v1.3-FR.pdf\" target=\"_blank\" rel=\"noopener\" target=\"_blank\" class=\"tano-file\"><span class=\"tano_download_icon\"><\/span><span class=\"tano_file_title\">T\u00e9l\u00e9charger le communiqu\u00e9 complet (PDF)<\/span><\/a> \n","protected":false},"excerpt":{"rendered":"<p>Lyon, France. Le 30 Juillet, 2021 &#8211; ENYO Pharma (ENYO), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui des donn\u00e9es de preuve de concept positives issues de l&#8217;\u00e9tude EYP001-203 de Vonafexor en association avec le pegInterf\u00e9ron chez des patients vir\u00e9miques atteints d&#8217;h\u00e9patite B chronique (CHB).<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/www.enyopharma.com\/fr\/enyo-pharma-annonce-les-premiers-resultats-intermediaires-du-vonafexor-eyp001-a-16-semaines-dans-deux-etudes-de-phase-2a-en-cours-chez-des-patients-atteints-dhepatite-b-chronique\/\">Lire la suite&nbsp;&raquo;<\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[17],"tags":[],"class_list":["post-3854","post","type-post","status-publish","format-standard","hentry","category-press-releases-fr"],"acf":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","rttpg_featured_image_url":null,"rttpg_author":{"display_name":"editorENYOPharma","author_link":"https:\/\/www.enyopharma.com\/fr\/author\/editorenyopharma\/"},"rttpg_comment":0,"rttpg_category":"<a href=\"https:\/\/www.enyopharma.com\/fr\/category\/press-releases-fr\/\" rel=\"category tag\">Press releases<\/a>","rttpg_excerpt":"Lyon, France. Le 30 Juillet, 2021 &#8211; ENYO Pharma (ENYO), une soci\u00e9t\u00e9 priv\u00e9e de biotechnologie au stade clinique et d\u00e9veloppant des candidats-m\u00e9dicaments innovants, a annonc\u00e9 aujourd&#8217;hui des donn\u00e9es de preuve de concept positives issues de l&#8217;\u00e9tude EYP001-203 de Vonafexor en association avec le pegInterf\u00e9ron chez des patients vir\u00e9miques atteints d&#8217;h\u00e9patite B chronique (CHB).Lire la suite&nbsp;&raquo;","_links":{"self":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3854","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/comments?post=3854"}],"version-history":[{"count":1,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3854\/revisions"}],"predecessor-version":[{"id":3855,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/posts\/3854\/revisions\/3855"}],"wp:attachment":[{"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/media?parent=3854"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/categories?post=3854"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.enyopharma.com\/fr\/wp-json\/wp\/v2\/tags?post=3854"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}